Morphic Holding Inc

Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022

Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Morphic Holding, Inc. (MORF): Can Its 7% Jump Turn into More Strength?

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic COO and CFO Marc Schegerin, M.D. will participate in panel discussion titled “Novel Approaches Tackling Autoimmune Conditions” at the BMO Biopharma Spotlight Series on Inflammation & Immunology on Wednesday April 6th 2022.

Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel

MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases

Morphic Therapeutic Announces Initiation of EMERALD-1 Phase 2a Clinical Trial of MORF-057 in Patients with Ulcerative Colitis

WALTHAM, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic President and CEO Praveen Tipirneni, M.D. will participate in a gastrointestinal and microbiome virtual panel discussion at the 42nd Annual Cowen Healthcare Conference at 10:30 AM ET on Wednesday, March 9th.

Morphic Announces Participation In Cowen 42nd Annual Healthcare Conference

Presented positive Phase 1 data for MORF-057

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2021

Morphic Holding, Inc. (MORF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Morphic Holding, Inc. (MORF) Upgraded to Buy: What Does It Mean for the Stock?

WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 PM ET.

Morphic Therapeutic to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference

αvβ8 inhibition demonstrates efficacy in a cancer model refractory to radiation and checkpoint inhibition

Morphic Presents Preclinical Data from αvβ8 Integrin Program at the SITC Annual Meeting

MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program in ulcerative colitis expected to begin 1Q22

Morphic Announces Corporate Highlights and Third Quarter 2021 Financial Results

Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Morphic Holding, Inc. (MORF) to Report a Decline in Earnings: What to Look Out for

Morphic is pursuing a multi-billion opportunity of replacing biologics modulating integrins with small molecules. The company is founded by the individual who discovered integrins and has built a unique technology platform to design selective oral therapies for integrins.

Morphic: Pioneering Integrin Medicines

WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are scheduled to take part in a fireside chat at the Jefferies Virtual Next Generation IBD Therapeutics Summit on October 19, 2021 at 3:15 p.m. ET.

Morphic to Participate in Jefferies IBD Therapeutics Summit

WALTHAM, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Nisha Nanda, Ph.D., to its Board of Directors. Dr. Nanda currently serves as the chief development officer for Loxo Oncology at Lilly.

Morphic Therapeutic Announces Appointment of Nisha Nanda, Ph.D., to Board of Directors

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -40.00% and -35.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Morphic Holding, Inc. (MORF) Reports Q2 Loss, Misses Revenue Estimates

MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program expected to begin 1Q22

Morphic Announces Corporate Highlights and Second Quarter 2021 Financial Results

Earnings Preview: Morphic Holding, Inc. (MORF) Q2 Earnings Expected to Decline

Morphic Therapeutic (NASDAQ: MORF) has announced additional data from its Phase 1 trial evaluating MORF-057 for inflammatory bowel disease (IBD).  The data were shared at the Congress of European Crohn's and Colitis Organization 2021 Virtual Congress.

Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study

MORF-057 well tolerated across all phase 1 cohorts

Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD

Call to discuss positive results from Phase 1 trial of MORF-057 to be presented at ECCO 2021 Virtual Congress Call to discuss positive results from Phase 1 trial of MORF-057 to be presented at ECCO 2021 Virtual Congress

Morphic Therapeutic to Host Analyst and Investor Call on July 9, 2021

Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Strength Seen in Morphic Holding, Inc. (MORF): Can Its 6% Jump Turn into More Strength?

Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies

Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO'21 Virtual Congress

WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are scheduled to present at the Jefferies Virtual Healthcare Conference on June 4, 2021 at 9:00 AM ET.

Morphic Therapeutic to Present at the Jefferies Virtual Healthcare Conference

Expanded research and development collaboration with Janssen for third integrin program

Morphic Announces Corporate Highlights and First Quarter 2021 Financial Results

Otello Stampacchia steps down, Vikas Goyal to leave Morphic Board at the end of current term Otello Stampacchia steps down, Vikas Goyal to leave Morphic Board at the end of current term

News for Morphic Holding Inc Stock (MORF)